Lyell Immunopharma, Inc.
LYEL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $124 | $99 | $120 | $106 |
| Short-Term Investments | $196 | $178 | $181 | $265 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $5 | $8 | $9 |
| Total Curr. Assets | $328 | $282 | $309 | $380 |
| Property Plant & Equip (Net) | $57 | $60 | $68 | $73 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $19 | $39 | $48 | $32 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $4 | $4 | $5 | $6 |
| Total NC Assets | $80 | $103 | $121 | $111 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $408 | $385 | $430 | $491 |
| Liabilities | – | – | – | – |
| Payables | $3 | $3 | $4 | $5 |
| Short-Term Debt | $0 | $9 | $8 | $8 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $29 | $25 | $29 | $40 |
| Total Curr. Liab. | $32 | $37 | $41 | $54 |
| LT Debt | $44 | $47 | $49 | $51 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $3 | $3 | $3 | $3 |
| Total NC Liab. | $47 | $50 | $52 | $54 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $55 | $57 | $59 |
| Total Liabilities | $79 | $87 | $93 | $108 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,479 | -$1,440 | -$1,397 | -$1,345 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,808 | $1,739 | $1,734 | $1,728 |
| Total Equity | $329 | $299 | $337 | $383 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $408 | $385 | $430 | $491 |
| Net Debt | -$79 | -$44 | -$63 | -$47 |